Compare iShares MSCI Japan ETF (EWJ) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Japan ETF vs Novo Nordisk A/S — how do they compare? iShares MSCI Japan ETF trades at $97.62 (market cap $23.87B), while Novo Nordisk A/S trades at $38.52 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 6.9× iShares MSCI Japan ETF's market cap, and Novo Nordisk A/S pays a 4.71% dividend while iShares MSCI Japan ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI Japan ETF for 56 Days and Novo Nordisk A/S for 116 Days on average.
| EWJ | NVO | |
|---|---|---|
Market Cap | $23.87B | $165.31B |
Volume | 5,412,820 | 11,432,838 |
Sector | Broad Market / Factor | Health |
52-Week High | $99.32 | $63.98 |
52-Week Low | $78.36 | $35.29 |
Typical Hold Time | 56 Days | 116 Days |
Enterprise Value | — | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $97.44, down 0.9% on the day amid mixed technical signals. The ETF shows neutral momentum with RSI readings around 50 and faces immediate resistance at $98. Recent news highlights Japan's monetary policy uncertainty as the Bank of Japan navigates rate hikes while facing fiscal challenges and yen volatility.
The outlook remains balanced with international ETF performance showing strength but Japanese equities facing headwinds from rising yields and currency pressures. Key risks include BOJ policy missteps and global bond market volatility, while potential catalysts include sustained international diversification trends and yen stabilization efforts.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
